News

InspireMD MGuard Prime Prime Embolic Protection Stent Clinical Trial

InspireMD Inc. said the first patient has been enrolled in the Master II IDE clinical trial to evaluate the safety and effectiveness of the MGuard Prime Embolic Protection Stent (EPS) in patients...

Abbott Technologies Acquires IDEV Technologies

Abbott announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional...

July 12, 2013 — Micell Technologies Inc. received CE mark approval for its MiStent sirolimus-eluting absorbable polymer coronary stent system. The MiStent SES is unique in providing local...

Xience Prime Orsiro Drug Eluting Stent BIO-GLOW II Clinical Study Biotronik Abbo

Primary end-point results from the BIOFLOW-II clinical study demonstrating the non-inferiority of the Biotronik Orsiro Hybrid Drug-Eluting Stent compared to Abbott's Xience Prime. These results...

Final six and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr. Mark Webster at the late-breaking clinical trials session of the EuroPCR...

Tryton Side Branch Stent Nordic-Baltic Bifurcation Study Group Clinical Trial

Tryton Medical Inc. announced that the Nordic-Baltic Bifurcation Study Group will investigate the Tryton Side Branch Stent. The trial is a prospective, controlled, randomized, multicenter clinical...

New long-term data from the DIVERGE study, presented at EuroPCR 2013 by Principal Investigator Dr. Stefan Verheye, Antwerp Cardiovascular Centre, ZNA Middelheim Hospital, Belgium, has shown that...

June 3, 2013 — OrbusNeich has launched the world's first dual-therapy stent to address the challenges of delayed healing of the coronary artery associated with monotherapy drug-eluting stents (DES...

Xience Xpedition 48 Abbott Vascular CE mark Europe

Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to...

mGuard stent, STEMI

InspireMD Inc. announced new six-month results from the MASTER trial demonstrating that the MGuard embolic protection stent (EPS) outperformed bare metal stents and drug-eluting stents in all-...

University of Maryland Medical Center Genetic-Testing Program Cardiac Stent

Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their genes. As part...

Elixer bioresorbable stent

Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve Novolimus-eluting bioresorbable coronary stent scaffold system. The scaffold is...

bioresorbable stent, zinc stent

University of Michigan researchers said the preliminary results of using biresorbable zinc stents were amazing, with corrosion rates exactly where they need to be for a stent successful platform...

For patients who received stents to restore blood flow through the main arteries supplying blood to the brain, inflating a tiny balloon inside the arteries after implantation of the stent ...

Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral Stent based on its investigation into a small number of complaints that the delivery system of the...

Stenting reopens completely blocked bowel arteries, preventing damage and even death from a condition that causes individuals severe pain and leads to excessive weight loss, notes research being...

Kidney failure patients on dialysis derive long-term benefit from the minimally invasive placement of a stent that improves the function of dialysis access grafts, according to 12-month clinical...

Zilver Vena

Cook Medical has launched the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent in the treatment of...

The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD...

Reva Medical Inc. announced that it has initiated patient enrollment with its ReZolve2 bioresorbable sirolimus-eluting coronary scaffold.